^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IMC-C103C

i
Other names: IMC-C103C, IMC C103C, RG-6290
Company:
Immunocore, Roche
Drug class:
TCR modulator, MAGE-A4 inhibitor
Related drugs:
1m
Enrollment change • Trial withdrawal • Combination therapy • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02
|
Tecentriq (atezolizumab) • IMC-C103C
9ms
IMC-C103C-101: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (clinicaltrials.gov)
P1/2, N=75, Terminated, Immunocore Ltd | N=144 --> 75 | Trial completion date: Feb 2024 --> Sep 2023 | Active, not recruiting --> Terminated; The Sponsor terminated the study and there is no further enrollment. Endpoints will not be assessed for this trial.
Enrollment change • Trial completion date • Trial termination • Combination therapy • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02
|
Tecentriq (atezolizumab) • IMC-C103C
1year
IMC-C103C-101: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (clinicaltrials.gov)
P1/2, N=144, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Feb 2024 | Trial primary completion date: Jul 2025 --> Sep 2023
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02
|
Tecentriq (atezolizumab) • IMC-C103C
2years
Phase 1 expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma (ESMO-IO 2022)
Pre-selection for MAGE-A4 expression was not required as a majority of OC express MAGE-A4 (H score ≥ 1) and tebentafusp demonstrated OS benefit and ctDNA reductions regardless of H score, although RECIST responses were enriched at higher H scores (Leach 2021). IMC-C103C is clinically active but the low MAGE expression may have resulted in few RECIST responses. Dose optimization and signal detection continue in MAGE-A4 pos pts with additional tumor types.
P1 data • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02 • MAGEA4 expression
|
Guardant360® CDx
|
Kimmtrak (tebentafusp-tebn) • IMC-C103C
3years
Phase 1 dose escalation of IMC-C103C, a CD3_MAGE-A4 T cell receptor (TCR) bispecific protein (ESMO-IO 2021)
Background TCR bispecific proteins (bsp) redirect polyclonal T cells to target intra/extracellular proteins in cancer, as validated by tebentafusp (CD3×gp100 TCR) with a survival benefit in metastatic uveal melanoma (HR 0.51). Legal entity responsible for the study Immunocore Ltd. Funding Immunocore Ltd.
P1 data • IO biomarker
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • MAGEA4 (Melanoma antigen family A, 4)
|
Kimmtrak (tebentafusp-tebn) • IMC-C103C
over3years
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (clinicaltrials.gov)
P1/2, N=144, Recruiting, Immunocore Ltd | Trial completion date: Apr 2023 --> Jul 2025 | Trial primary completion date: Oct 2021 --> Jul 2025
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
Tecentriq (atezolizumab) • IMC-C103C
over4years
[VIRTUAL] A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101). (ASCO 2020)
Tebentafusp is being further evaluated in combination with durvalumab and tremelimumab. IMC-C103C monotherapy dose escalation is in progress. Research Funding: Immunocore Ltd, Pharmaceutical/Biotech Company
Clinical • P1/2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1)
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • Kimmtrak (tebentafusp-tebn) • IMC-C103C